Avalyn Pharma Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Genoa Pharmaceuticals, Inc. (to 2017)
Previously recorded as Windward Pharma, Inc. (to 2020)
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 7, 2027The maintenance fee for Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof (US 10,610,536) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Inhaled Imatinib for Treatment of Pulmonary Arterial Hypertension (PAH) (US 11,980,689) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,224,592 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,452,718 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,559,520 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,226,407 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,092,552 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,105,356 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,980,689 | Inhaled Imatinib for Treatment of Pulmonary Arterial Hypertension (PAH) In force · Medium confidence | In force | Medium confidence | |
| US 9,770,443 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,028,966 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,610,536 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 2 abandoned · 1 no status recorded
Showing 1 to 10 of 12, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/014,801 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof | Jan 9, 2025 | Pending |
| 18/974,588 | Nintedanib and Nintedanib Combination Dry Powder Compositions and Uses | Dec 9, 2024 | Pending |
| 18/961,095 | Nintedanib and Nintedanib Combination Dry Powder Compositions and Uses | Nov 26, 2024 | Pending |
| 18/887,514 | Specially Formulated Compositions of Inhaled Nintedanib and Nintedanib Salts | Sep 17, 2024 | Pending |
| 18/664,718 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof | May 15, 2024 | Pending |
| 18/662,936 | Inhaled Imatinib for Treatment of Pulmonary Arterial Hypertension (PAH) | May 13, 2024 | Abandoned |
| 18/171,930 | Nebulizer Device Optimization for Improved Aerosol Parameters and Uses Thereof | Feb 21, 2023 | Pending |
| 17/576,830 | Aerosol Pirfenidone and Pyridone Analog Compounds and Uses Thereof | Jan 14, 2022 | Pending |
| 17/542,262 | Aerosol Tyrosine Kinase Inhibitor Compounds and Uses Thereof | Dec 3, 2021 | Pending |
| 18/042,375 | Nebulizer Device Optimization for Improved Aerosol Parameters and Uses Thereof | Sep 22, 2021 | Pending |
10 of 12 applications shown.
Pro members see all 12 published applications.